公开(公告)号：US20220409724A1

公开(公告)日：2022-12-29

申请号：US17772468

申请日：2020-10-28

Applicant: Eisai R&D Management Co., Ltd. ,  Merck Sharp & Dohme Corp. ,  MSD International GmbH

Inventor： Yoichi OZAWA ,  Yasuhiro FUNAHASHI ,  Yu KATO

IPC: A61K39/395 ,  A61P35/00 ,  A61K31/47 ,  A61K31/53

Abstract: The present disclosure describes a combination therapy comprising an antagonist of Programmed Death 1 receptor (PD-1), a lenvatinib or a pharmaceutically acceptable salt thereof, and (6S,9aS)-N-benzyl-8-({6-[3-(4-ethylpiperazin-1-yl)azetidin-1-yl]pyridin-2-yl}methyl)-6-(2-fluoro-4-hydroxybenzyl)-4,7-dioxo-2-(prop-2-en-1-yl)hexahydro-2H-pyrazino[2,1-c][1,2,4]triazine-1(6H)-carboxamide (E7386) or a pharmaceutically acceptable salt thereof,—and the use of the combination therapies for the treatment of a cancer.

公开(公告)号：US20230330081A1

公开(公告)日：2023-10-19

申请号：US18030207

申请日：2021-10-26

Applicant: EISAI R&D MANAGEMENT CO., LTD.

Inventor： Taisuke HOSHI ,  Yu KATO ,  Yoichi OZAWA ,  Satoshi KAWANO ,  Kotaro KODAMA ,  Saori MIYANO

IPC: A61K31/4545 ,  A61P35/00

CPC classification number: A61K31/4545 ,  A61P35/00 ,  A61K2039/505

Abstract: Provided is a pharmaceutical composition for treating a tumor, comprising 5-((2-(4-(1-(2-hydroxyethyl)piperidin-4-yl)benzamide)pyridin-4-yl)oxyl-6-(2-methoxyethoxy)-N-methyl-1H-indole-1-carboxamide or its pharmaceutically acceptable salt, which is to be administered in combination with a PD-1 antagonist.

公开(公告)号：US20170100367A1

公开(公告)日：2017-04-13

申请号：US15314160

申请日：2015-05-27

Applicant: Bruce A. Littlefield ,  Eisai R&D Management Co., Ltd.

Inventor： Makoto ASANO ,  Bruce A. LITTLEFIELD ,  Junji MATSUI ,  Martin OLIVO ,  Yoichi OZAWA ,  Yanke YU

IPC: A61K31/357 ,  A61K31/7068 ,  A61K31/282 ,  A61K31/704 ,  A61K31/427 ,  A61K9/00 ,  A61K31/337

Abstract: The invention features methods and kits for use in treating cancer in a patient in need thereof by administering eribulin or a pharmaceutically-acceptable salt thereof (e.g., eribulin mesylate) prior to a second agent.